E
EOS (Ethical Oncology Science)
Biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.
About EOS (Ethical Oncology Science)
Ethical Oncology Science (EOS) S.p.A. operated as a private Italian biopharmaceutical firm focused on developing targeted cancer therapies. Founded in June 2006, the Milan-based company was established by a team of experienced bio-entrepreneurs: Silvano Spinelli, who served as CEO and Chairman; Gabriella Camboni, the Chief Operating Officer; and Ennio Cavalletti, who was the VP of Operations. The founding team was composed of seasoned professionals with extensive backgrounds in translational medicine and a successful track record in oncology drug development.
The company's core asset was lucitanib, an oral drug candidate. EOS held the exclusive global development and commercialization rights for lucitanib, excluding China, which it acquired from Advenchen Laboratories LLC. The business strategy centered on advancing this asset through clinical trials and forming strategic partnerships to maximize its market reach. In 2012, EOS executed a significant licensing agreement, sublicensing the European and rest-of-world rights (excluding China) for lucitanib to the French pharmaceutical company Les Laboratoires Servier. This move secured a collaborator for development and future commercialization in those territories.
Lucitanib is a dual-selective inhibitor that targets the tyrosine kinase activity of fibroblast growth factor (FGF) receptors 1 and 2, as well as vascular endothelial growth factor (VEGF) receptors 1 through 3. By simultaneously inhibiting these two validated pathways involved in tumor growth and angiogenesis (the formation of new blood vessels), the drug was positioned to treat various cancers. The initial clinical development program focused on patients with FGF-aberrant breast cancer, a group representing about 25% of breast cancer cases. Clinical trials, which began in Europe in July 2010, showed objective responses in this patient group and also in patients with tumors sensitive to angiogenesis inhibitors, such as renal cell and thyroid cancer.
The company's journey culminated in November 2013 when it was acquired by Clovis Oncology, a US-based biopharmaceutical company. The transaction involved an upfront payment of $200 million, comprised of stock and cash, with substantial additional milestone payments contingent on regulatory approvals and sales targets. Following the acquisition, Clovis Oncology gained the U.S. and Japan rights to lucitanib and continued its development in collaboration with Servier.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2013 | $200M | $200M | Clovis Oncology | — |
| SERIES A✓Equity / VC | Jun 2009 | $17M | $68M | Aescap · Sofinnova Partners | — |
Growth signals
Latest recorded traffic for EOS (Ethical Oncology Science) is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EOS (Ethical Oncology Science) in the Milan ecosystem
The EOS (Ethical Oncology Science) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Aescap
Sofinnova Partners
Other known investors2 additional known investors
Clovis Oncology
XYence
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about EOS (Ethical Oncology Science) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EOS (Ethical Oncology Science)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








